MONTANA MOLECULAR LLC — SBIR/STTR Competitive Profile

Aggregate SBIR/STTR award history for MONTANA MOLECULAR LLC, built entirely from public federal award records. Free competitive intelligence — no login required.

Phase mix

Funding agencies

Awards by year

Places of performance

Firms like MONTANA MOLECULAR LLC

See the companies with the most overlapping technology domains and funding agencies, ranked by a weighted-overlap similarity score.

Recent awards

AwardAgencyAmountProgramStart
1R44AI165188-01A1 Department of Health and Human Services $600,000 SBIR · Phase II 2022-05-13
1R44DA050357-01 Department of Health and Human Services $221,097 SBIR · Phase I 2019-09-30
2R44GM125390-02 Department of Health and Human Services $1,235,017 SBIR · Phase II 2019-07-01
1R43NS108817-01 Department of Health and Human Services $250,833 SBIR · Phase I 2018-09-01
1R43GM125390-01 Department of Health and Human Services $193,000 SBIR · Phase I 2017-08-21
1430878 National Science Foundation $568,652 SBIR · Phase II 2014-11-26
9R44NS082222-02A1 Department of Health and Human Services $1,167,851 SBIR · Phase II 2014-01-15
1248138 National Science Foundation $149,423 SBIR · Phase I 2013-01-01
1R43MH096670-01A1 Department of Health and Human Services $348,182 SBIR · Phase I

Frequently asked questions

How many SBIR/STTR awards has MONTANA MOLECULAR LLC won?

MONTANA MOLECULAR LLC has won 9 SBIR/STTR awards worth $4,734,055 in the public federal award records SBIR Signal tracks, including 5 Phase I and 4 Phase II award(s).

Which agencies fund MONTANA MOLECULAR LLC?

MONTANA MOLECULAR LLC's awards come from 2 agencies on record; its top funder is Department of Health and Human Services.

What technology areas does MONTANA MOLECULAR LLC work in?

Based on its award history, MONTANA MOLECULAR LLC works in a range of technology areas.

How do I find firms similar to MONTANA MOLECULAR LLC?

Sign in and open the 'firms like this' view on the profile to see the companies with the most overlapping technology domains and funding agencies.